Previous 10 | Next 10 |
Upfront $120 million tranche used to finance the full settlement of existing convertible notes held by Deerfield Management Company Deerfield Management Company to take equity as part of the settlement of existing convertible notes Owl Rock to make $6.25 million equity...
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q2 2022 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q2 2022 Earnings Conference Call August 09, 2022, 08:30 AM ET Company Participants Amanda Hamilton - IR Manager Ameet Mallik - CEO Jennifer Herron - Chief Commercial Officer Jenn Creel - CFO Joe Camardo - Chief Medical Officer ...
ADC Therapeutics press release ( NYSE: ADCT ): Q2 Non-GAAP EPS of -$0.73. Revenue of $17.29M (+359.8% Y/Y) misses by $13.93M . “The ZYNLONTA® launch is advancing steadily as we continue to increase awareness and advocacy. There is significant opportunit...
ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $17.3 million in the second quarter of 2022 Ex-U.S. ZYNLONTA license agreement with Sobi ® facilitates global patient access and extends cash runway into early 2025 Company to host conferen...
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates. To access the conference call, please register her...
ADCT-601 binds to AXL, a cancer antigen expressed in solid tumors such as sarcoma and is associated with resistance to chemotherapy ADCT-601 was observed to have a manageable tolerability profile as monotherapy in Phase 1a Pre-clinical studies demonstrate anti-tumor ac...
LOTIS-9 trial targets unfit, frail and elderly patients with previously untreated DLBCL representing a significantly underserved patient population ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in LOTIS-9, a Phase 2 clinical trial evaluati...
LOTIS-5 is intended to serve as the basis for a supplemental BLA (sBLA) in the U.S. and China in second-line transplant ineligible DLBCL Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals (“Overland”) and ADC Therapeutics SA (NYSE: ADC...
Swedish Orphan Biovitrum ( OTCPK:BIOVF ) (Sobi) signed a licensing agreement to develop and commercialize ADC Therapeutics' ( NYSE: ADCT ) Zynlonta (loncastuximab tesirine) for all blood and solid tumor indications outside the U.S., Greater China, Singapore and Ja...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...